A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses

le Boyd, Zachary S., Raja, Rajiv, Johnson, Stephanie, Eberhard, David A., Lackner, Mark R.
Foilsithe 2009

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

le Sangro, Bruno, Melero, Ignacio, Wadhawan, Samir, Finn, Richard S., Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Yau, Thomas, Furuse, Junji, Park, Joong-Won, Boyd, Zachary, Tang, Hao (Tracy), Shen, Yun, Tschaika, Marina, Neely, Jaclyn, El-Khoueiry, Anthony
Foilsithe in J Hepatol (2020)

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

le Xiao, Yuanyuan, Rabe, Christina, Kowanetz, Marcin, Powles, Thomas, Vogelzang, Nicholas J, Petrylak, Daniel P, Loriot, Yohann, Denker, Mitchell, Nakamura, Rin, Wu, Qun J, Sumiyoshi, Teiko, Boyd, Zachary, Teng, Siew-leng M, Shen, Xiaodong, Fine, Gregg, Chen, Daniel S, Hegde, Priti S
Foilsithe in J Immunother Cancer (2014)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

le Powles, Thomas, Nickles, Dorothee, Van Allen, Eliezer, Chappey, Colombe, Zou, Wei, Kowanetz, Marcin, Kadel, Edward, Denker, Mitchell, Boyd, Zachary, Vogelzang, Nicholas, Kim, Joseph, Bellmunt, Joaquim, Loriot, Yohann, Drake, Charles G, O'Hear, Carol, Fasso, Marcella, Hegde, Priti, Mariathasan, Sanjeev
Foilsithe in J Immunother Cancer (2015)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

le Vennapusa, Bharathi, Baker, Brian, Kowanetz, Marcin, Boone, Jennifer, Menzl, Ina, Bruey, Jean-Marie, Fine, Gregg, Mariathasan, Sanjeev, McCaffery, Ian, Mocci, Simonetta, Rost, Sandra, Smith, Dustin, Dennis, Eslie, Tang, Szu-Yu, Damadzadeh, Bita, Walker, Espen, Hegde, Priti S., Williams, J. Andrew, Koeppen, Hartmut, Boyd, Zachary
Foilsithe in Appl Immunohistochem Mol Morphol (2019)

Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

le Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F
Foilsithe in Lancet (2016)